[Clinical analysis of 102 blood disease patients with gram positive cocci infection treated with Linezolid].
OBJECTIVE
To observe the efficacy and safety of linezolid for the treatment of gram positive coccus infections in hematological disease patients.


METHODS
One hundred and two hematological disease patients with suspected or proven gram positive coccus bacteria infection were enrolled in this study. Linezolid was given at a dosage of 600 mg, iv, q12h. The mean treatment period was (10.82 ± 5.12) days (1 to 51 days) with 74.5% over 7 d and 51.0% over 10 d.


RESULTS
Among 102 patients, 57 were male, 45 female aged 11 to 81 years, with a mean of (45.26 ± 19.15) years. Ninety four cases were nosocomial infection (92.2%) and 8 community infection (7.8%); There were pneumonia in 80 (78.4%), septicemia in 11 (10.8%), and infection of other organsin 11 (10.8%); Forty five cases were proven gram positive coccus bacteria infection, and 57 were suspected infection; Fifty one bacteria strains were isolated from cultivated samples of proven patients, in which 22 were staphylococcus aureus with 19 methicillin resistant 13 hemolytic streptococcus, 9 staphylococcus epidermidis with 7 methicillin resistant 6 enterococcus faecom, and 1 enterococcus hirae. Seven cases were mixed with one kind gram negative bacillus infection, 4 mixed with two kinds of gram negative bacillus infection, and 12 mixed with fungal infection; Total clinical response rates by ITT (intention to treatment) analysis was 69.6%, in which 40 (39.2%) were curative and 31 (30.4%) obviously effective; PP (per-protocol) analysis was 70.9%, in which 39 (41.9%) were curative and 27 (29.0%) obviously effective. Bacteria clearance rate was 70.6%, and in this group the clinical effective rate was 88.9%; Adverse effect rate was 2.9%, being transient thrombocytopenia and increased transaminase.


CONCLUSIONS
Linezolid is a safe and effective antibiotic used in hematological disease patients complicated with infections of gram positive coccus.
Department of Hematology/Oncology, General Hospital of Tianjin Medical University, Tianjin 300052, China.
Jing
J
Guan
Rong
R
Fu
Er-Bao
EB
Ruan
Yong
Y
Liang
Wen
W
Qu
Guo-Jin
GJ
Wang
Xiao-Ming
XM
Wang
Hong
H
Liu
Yu-Hong
YH
Wu
Jia
J
Song
Hua-Quan
HQ
Wang
Li-Min
LM
Xing
Zong-Hong
ZH
Shao
D000081:Acetamides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003428:Cross Infection / Q000382:microbiology; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy; D006095:Gram-Positive Cocci; D006402:Hematologic Diseases / Q000188:drug therapy; D006801:Humans; D000069349:Linezolid; D023303:Oxazolidinones; D013211:Staphylococcus aureus
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000069349:Linezolid